The Interface Between Kinetics and Dynamics: Physiological Modeling of Two Estrogen Receptor Agonists

Justin Teeguarden, PhD, DABT
Pacific Northwest National Laboratory


West to East with Paul West

Much of today's public anxiety about science is that apprehension that we may be forever overlooking the whole by an endless, obsessive preoccupation with the parts.


Lewis Thomas

Computational Toxicology!

The Pharmacokinetic Pharmacodynamic Interface



Integrating Protein Binding, Receptor Binding and Clearance Using *In Vivo* Models




Do Saturable Binding Processes Affect Dosimetry?

- Is response ~ receptor occupancy?
- Do the multiple binding equilibria affect dosimetry? Under what conditions?
- Does protein binding affect clearance and potency?

Serum Protein Binding Restricts Availability

Estrogen Receptor (ER) Bound as a Function of Estradiol Concentration in the Presence and Absence of Male Human Serum



Adapted from: Teeguarden, J. G., and Barton, H. A. (2004). Risk Anal 24, 751-70.


Clearance Affects Potency


Potency Relative to E2

| Compound | - Clea | + Clearance | |
|-------------|----------|-------------|-----------|
| | No Serum | Rat Serum | Rat Serum |
| Estradiol | 1 | 1 | 1 |
| Genistein | 0.02 | 0.16 | 0.32 |
| Bisphenol A | 0.0005 | 0.0009 | 0.002 |

Estradiol Pharmacokinetics and Receptor Binding Model


Estradiol PBPK Model






Hepatic Extraction Model

Does Binding Affect Hepatic Clearance?




Yes, Binding Affects Clearance




 Disassociation of estradiol during transit through the liver increases the "available" fraction of estradiol for diffusion and metabolism

E2 Pharmacokinetics in Intact Female Rats




IV E2 pharmacokinetics in intact female rats. ●,
plasma; ■, uterus; ▼, liver. Dotted line: Diffusion
limited uterine uptake

E2 Pharmacokinetics in OVX Female Rats




IV E2 pharmacokinetics in OVX female rats. 2.5 (closed circles) and 25 (open circles) µg E2/kg. Dotted line: purfusion limited uterine uptake.


IV Route E2 Pharmacokintics in Male Rats



E2 Pharmacokintics Intraduodenal Administration in Male Rats




ER Binding and Uterine Response




- Subcutaneous E2, intact rats (Naciff et al, 2003)
- Uterine response
 - 0.1 µg/kg/day—100% of control
 - 1 μg/kg/day—380% of control
 - 10 µg/kg/day—430% of control


Does Estradiol and Estrone In Milk Pose a Risk to Adolescents?




10 pg of E2 and 10 pg of Estrone administered as E2




Bisphenol A Model



Rat Blood Kinetics





Tissue Response is Related to Receptor Occupancy

Correlating Uterine Receptor Dose Metrics And Uterine Response

| Oral Dose | Percent | Percent | Uterine Weight |
|-----------|-----------------|--------------|--------------------------|
| (mg/kg) | Occupancy | Occupancy | (% control) ^a |
| | Without Binding | With Binding | |
| 0 | 0 | 0 | 100 |
| 10 | 9.6 | 0.63 | 100 |
| 100 | 73.1 | 14.0 | 100 |
| 200 | 84.8 | 25.2 | 124 |
| 800 | 96.4 | 62 | 200 |
| | ER-BPA | ER-BPA | |
| | Complex AUC | Complex AUC | |
| | Without Binding | With Binding | |
| 0 | 0 | 0 | 100 |
| 10 | 0.025 | 0.002 | 100 |
| 100 | 0.19 | 0.04 | 100 |
| 200 | 0.23 | 0.07 | 124 |

0.17

200

- Response is not related to receptor occupancy in the absence of protein binding
- Response is best related to receptor occupancy when protein binding is considered

0.26

800

Response is not related to oral dose

a Twomey, 1998

Conclusions


- Protein binding can influence the biologically active fraction of a chemical in blood or a tissue
 - Critical for many pharmaceuticals
 - Affect cross species, sex and life-stage extrapolations
- Modeling at the PK/PD interface reveals important dose response relationships—at lease for BPA so they are impactful
- Models like these are reasonably easy to develop and parameterize.

Acknowledgements


- Hugh Barton, EPA
- David Plowchalk, Pfizer
- American Chemistry Council and the American Plastics Council

Model This






Why Model Receptor Binding?




Does Estradiol and Estrone In Milk Pose a Risk to Adolescents?



Clearance Affects Potency

Potency Relative to E2

| | , | In Vitro | In Vivo |
|-------------------------------|------------|-----------------|-----------|
| Compound | Serum Free | Adult Rat Serum | Adult Rat |
| Estradiol | 1 | 1 | 1 |
| Genistein | 0.02 | 0.16 | 0.32 |
| Bisphenol A | 0.0005 | 0.0009 | 0.002 |
| Weak Agonist – Slow clearance | 0.0005 | 0.0009 | 0.02 |
| Weak Agonist – Fast clearance | 0.0005 | 0.0009 | 0.0002 |



Estradiol and Bisphenol A

Estradiol

- ~ 2% non-bound (free) in human blood
- Significant binding to SHBG and albumin
- ~ 4% free in rat blood, less during pregnancy
- Significant binding to α -fetoprotein and albumin


• BPA

- ~ 7 % free in human blood (mostly albumin binding)
- ~ 6% free in rat blood (mostly albumin binding)

Bisphenol A

- Weakly estrogenic plasticizing compound
- Acts through the estrogen receptor
- Highly bound in the blood
- Dose-response for rodents:
 - Affected by non linear kinetics?
 - Affected by protein binding in blood?
 - Is response related to receptor binding?
- Uterotrophic response: Linking receptor binding, tissue dynamics and a common reproductive/developmental toxicology endpoint

Integrating Protein Binding, Receptor Binding and Clearance Using *In Vivo* Models



Basic Principles: Hormone Transport

- The Free Hormone Transport Hypothesis
 - Only free hormone can cross cell membranes (from blood to tissues)
 - Tissue receptors can be in equilibrium with free and (sometimes) some portion of the protein bound
 - This means the extent and affinity of binding in blood is an important determinant of biological activity